| Literature DB >> 33087342 |
Yuji Komorita1,2, Masanori Iwase3,4, Hiroki Fujii1, Toshiaki Ohkuma1, Hitoshi Ide1, Tamaki Jodai-Kitamura1, Masahito Yoshinari1, Yutaro Oku1, Taiki Higashi1, Udai Nakamura1, Takanari Kitazono1.
Abstract
INTRODUCTION: The impact of consuming green tea or coffee on mortality in patients with diabetes is controversial. We prospectively investigated the impact of each beverage and their combination on mortality among Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In all, 4923 patients (2790 men, 2133 women) with type 2 diabetes (mean age, 66 years) were followed prospectively (median, 5.3 years; follow-up rate, 99.5%). We evaluated the amount of green tea and coffee consumed using self-administered questionnaires.Entities:
Keywords: green tea catechin; mortality; nutritional epidemiology; type 2 diabetes
Mesh:
Substances:
Year: 2020 PMID: 33087342 PMCID: PMC7577036 DOI: 10.1136/bmjdrc-2020-001252
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Baseline clinical characteristics according to amount of green tea or coffee consumed among Japanese participants with type 2 diabetes
| Green tea consumption | Coffee consumption | |||||||
| None | ≤1 cup /d | 2–3 cups/d | ≥4 cups/d | None | <1 cup /d | 1 cup/d | ≥2 cups/d | |
| 607 | 1143 | 1389 | 1784 | 994 | 1306 | 963 | 1660 | |
| Age (years) | 64.6±10.2 | 62.5±10.8 | 65.7±9.8 | 67.3±9.7 | 69.0±10.0 | 66.4±10.2 | 65.6±10.1 | 62.3±9.5 |
| Male sex (%) | 60.3 | 64.3 | 60.5 | 47.6 | 50.6 | 54.7 | 53.3 | 63.9 |
| Duration of diabetes (years) | 14.9±10.3 | 14.8±10.4 | 15.9±10.6 | 16.0±10.6 | 16.3±10.9 | 15.5±10.6 | 15.5±10.3 | 15.2±10.4 |
| BMI (kg/m2) | 23.9±3.4 | 24.1±3.8 | 23.5±3.7 | 23.7±3.9 | 23.7±3.7 | 23.9±3.8 | 23.9±4.0 | 23.6±3.6 |
| Current smoker (%) | 24.9 | 20.7 | 18.85 | 15.1 | 12.6 | 12.1 | 15.1 | 29.2 |
| Current alcohol intake (%) | 40.5 | 45.7 | 42.6 | 31.8 | 30.5 | 38.8 | 40.9 | 43.5 |
| Depressive symptoms (%) | 10.2 | 9.6 | 7.5 | 8.7 | 9.7 | 9.3 | 7.5 | 8.6 |
| LTPA (MET h/week) | 12.3±16.1 | 11.2±14.7 | 11.5±14.0 | 12.0±15.3 | 11.3±14.8 | 11.3±14.9 | 12.5±15.2 | 11.8±14.8 |
| Sleep duration (h/day) | 6.8±1.4 | 6.7±1.3 | 6.9±1.3 | 6.9±1.5 | 7.0±1.6 | 6.9±1.4 | 6.9±1.3 | 6.7±1.3 |
| HbA1c (%) | 7.4±1.0 | 7.4±1.0 | 7.4±1.0 | 7.5±1.1 | 7.4±1.1 | 7.4±1.0 | 7.4±1.0 | 7.5±1.1 |
| HbA1c (mmol/mol) | 57.3±10.8 | 57.4±11.2 | 57.4±10.7 | 58.4±12.2 | 57.4±11.8 | 57.1±11.2 | 57.8±11.0 | 58.5±11.6 |
| eGFR (ml/min/1.73 m2) | 73.3±23.7 | 78.6±21.8 | 74.2±21.4 | 73.5±20.9 | 69.7±23.1 | 73.5±21.0 | 75.5±22.2 | 78.6±20.4 |
| UACR (mg/g・Cr) | 246±780 | 175±690 | 178±583 | 195±620 | 251±771 | 209±666 | 189±695 | 145±509 |
| LDL cholesterol (mmol/l) | 2.9±0.7 | 2.8±0.7 | 2.9±0.7 | 2.9±0.7 | 2.8±0.7 | 2.8±0.7 | 2.8±0.7 | 2.9±0.7 |
| HDL cholesterol (mmol/l) | 1.4±0.4 | 1.5±0.4 | 1.5±0.4 | 1.5±0.4 | 1.4±0.4 | 1.4±0.4 | 1.5±0.4 | 1.5±0.4 |
| Systolic blood pressure (mmHg) | 130±18 | 130±17 | 130±17 | 132±17 | 131±18 | 132±17 | 131±17 | 129±16 |
| Diastolic blood pressure (mmHg) | 75±11 | 75±11 | 75±11 | 74±11 | 73±11 | 74±11 | 75±11 | 75±10 |
| History of CVD (%) | 24.2 | 22.1 | 20.7 | 21.4 | 25.7 | 22.8 | 20.9 | 18.9 |
| History of cancer (%) | 7.1 | 8.5 | 9.4 | 10.7 | 11.1 | 9.4 | 10.4 | 7.7 |
| Insulin therapy (%) | 32.8 | 27.7 | 27.0 | 29.6 | 30.4 | 24.9 | 28.7 | 31.1 |
| Oral hypoglycemic agent (%) | 59.6 | 64.2 | 65.5 | 62.3 | 61.2 | 64.9 | 64.1 | 62.9 |
| Antihypertensive drugs (%) | 55.7 | 51.6 | 54.6 | 54.4 | 61.9 | 57.4 | 56.5 | 45.1 |
| Antiplatelet drugs (%) | 28.2 | 22.9 | 24.1 | 25.8 | 29.4 | 26.9 | 25.2 | 20.6 |
| Statin (%) | 43.0 | 44.4 | 41.0 | 44.7 | 43.9 | 40.8 | 48.4 | 42.3 |
| Coffee drinker | 75.1 | 87.0 | 81.5 | 75.5 | – | – | – | – |
| Green tea drinker (>0 cup/d, %) | – | – | – | – | 84.8 | 89.6 | 88.5 | 87.4 |
Values are expressed as means±SD or percentages.
BMI, body mass index; Cr, creatinine; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rates; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LTPA, leisure-time physical activity; MET, metabolic equivalent; UACR, urinary albumin creatinine ratio.
All-cause and cause-specific mortality according to amount of green tea or coffee consumed among Japanese participants with type 2 diabetes
| Green tea consumption | P for trend | Coffee consumption | P for trend | |||||||
| None | ≤1 cup/d | 2–3 cups/d | ≥4 cups/d | None | <1 cup/d | 1 cup/d | ≥2 cups/d | |||
| All-cause mortality | ||||||||||
| No of death | 50 | 74 | 87 | 98 | 94 | 91 | 58 | 66 | ||
| Incidence (/1000PYs) | 15.8 | 12.3 | 11.9 | 10.4 | 18.2 | 13.2 | 11.5 | 7.5 | ||
| HR (95% CI) | ||||||||||
| Age- and sex- adjusted | 1.0 (ref.) | 0.87 (0.61–1.24) | 0.71 (0.50–1.00) | 0.60 (0.43–0.85) | 0.001 | 1.0 (ref.) | 0.81 (0.60–1.08) | 0.76 (0.55–1.05) | 0.58 (0.41–0.80) | 0.001 |
| Multivariable-adjusted | 1.0 (ref.) | 0.85 (0.60–1.22) | 0.73 (0.51–1.03) | 0.60 (0.42–0.85) | 0.002 | 1.0 (ref.) | 0.88 (0.66–1.18) | 0.81 (0.58–1.13) | 0.59 (0.42–0.82) | 0.002 |
| +Coffee | 1.0 (ref.) | 0.88 (0.61–1.26) | 0.73 (0.51–1.03) | 0.60 (0.42–0.85) | 0.001 | – | – | – | – | |
| +Green tea | – | – | – | – | 1.0 (ref.) | 0.88 (0.66–1.18) | 0.81 (0.58–1.13) | 0.58 (0.42–0.81) | 0.002 | |
| Cancer mortality | ||||||||||
| No of death | 16 | 26 | 39 | 33 | 32 | 33 | 22 | 27 | ||
| Incidence (/1000PYs) | 5.1 | 4.3 | 5.4 | 3.5 | 6.2 | 4.8 | 4.4 | 3.1 | ||
| HR (95% CI) | ||||||||||
| Age- and sex- adjusted | 1.0 (ref.) | 0.96 (0.52–1.80) | 0.98 (0.55–1.76) | 0.63 (0.34–1.15) | 0.09 | 1.0 (ref.) | 0.87 (0.53–1.41) | 0.86 (0.50–1.49) | 0.72 (0.43–1.23) | 0.26 |
| Multivariable-adjusted | 1.0 (ref.) | 0.96 (0.52–1.80) | 1.02 (0.57–1.83) | 0.65 (0.35–1.19) | 0.12 | 1.0 (ref.) | 0.92 (0.56–1.49) | 0.94 (0.54–1.62) | 0.78 (0.45–1.34) | 0.41 |
| +Coffee | 1.0 (ref.) | 0.98 (0.53–1.84) | 1.02 (0.57–1.84) | 0.65 (0.35–1.19) | 0.11 | – | – | – | – | |
| +Green tea | – | – | – | – | 1.0 (ref.) | 0.92 (0.56–1.50) | 0.94 (0.54–1.62) | 0.77 (0.45–1.33) | 0.39 | |
| Cardiovascular mortality | ||||||||||
| No of deaths | 13 | 22 | 15 | 26 | 23 | 23 | 14 | 16 | ||
| Incidence (/1000PYs) | 4.1 | 3.7 | 2.1 | 2.8 | 4.5 | 3.3 | 2.8 | 1.8 | ||
| HR (95% CI) | ||||||||||
| Age- and sex- adjusted | 1.0 (ref.) | 0.97 (0.49–1.93) | 0.47 (0.23–1.00) | 0.62 (0.32–1.22) | 0.06 | 1.0 (ref.) | 0.82 (0.46–1.46) | 0.72 (0.37–1.40) | 0.52 (0.27–1.01) | 0.049 |
| Multivariable-adjusted | 1.0 (ref.) | 1.03 (0.51–2.05) | 0.53 (0.25–1.13) | 0.66 (0.33–1.31) | 0.09 | 1.0 (ref.) | 0.92 (0.51–1.65) | 0.83 (0.42–1.62) | 0.53 (0.27–1.04) | 0.06 |
| +Coffee | 1.0 (ref.) | 1.06 (0.53–2.12) | 0.54 (0.25–1.14) | 0.65 (0.33–1.29) | 0.08 | – | – | – | – | |
| +Green tea | – | – | – | – | 1.0 (ref.) | 0.92 (0.51–1.64) | 0.82 (0.42–1.61) | 0.52 (0.26–1.02) | 0.055 | |
Multivariate adjustments included age, sex, BMI, diabetes duration, current smoking habit, current alcohol intake, LTPA, sleep duration, HbA1c, UACR, systolic blood pressure, LDL cholesterol, history of CVD and cancer.
BMI, body mass index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; LTPA, leisure-time physical activity; UACR, urinary albumin creatinine ratio.
Figure 1Combined effects of green tea and coffee consumption on all-cause mortality in patients with type 2 diabetes. The estimates are adjusted for age, sex, BMI, diabetes duration, current smoking habit, current alcohol intake, LTPA, sleep duration, HbA1c, UACR, systolic blood pressure, LDL cholesterol, history of CVD and cancer. *P<0.05 vs the reference group (NO consumption of green tea and coffee). BMI, body mass index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; LTPA, leisure-time physical activity; UACR, urinary albumin creatinine ratio.
Multivariate-adjusted HR and 95% CIs of green tea and coffee consumption for all-cause mortality in patients with type 2 diabetes
| Green tea consumption | Coffee consumption | |||
| No | <1 cup/d | 1 cup/d | ≥2 cups/d | |
| No | ||||
| Event no. /at risk | 14/151 | 13/136 | 11/111 | 12/209 |
| HR (95% CI) | 1.0 (ref.) | 0.95 (0.45–2.04) | 1.17 (0.53–2.59) | 0.76 (0.35–1.66) |
| ≤1 cup/d | ||||
| Event no. /at risk | 17/149 | 22/305 | 15/230 | 20/459 |
| HR (95% CI) | 0.93 (0.45–1.92) | 0.95 (0.48–1.86) | 0.85 (0.41–1.77) | 0.62 (0.31–1.23) |
| 2–3 cups/d | ||||
| Event no. /at risk | 30/257 | 20/361 | 18/271 | 19/500 |
| HR (95% CI) | 0.98 (0.52–1.86) | 0.59 (0.30–1.16) | 0.81 (0.40–1.64) | 0.49 (0.24–0.99) |
| ≥4 cups/d | ||||
| Event no. /at risk | 33/437 | 36/504 | 14/351 | 15/492 |
| HR (95% CI) | 0.72 (0.38–1.35) | 0.74 (0.40–1.38) | 0.42 (0.20–0.88) | 0.37 (0.18–0.77) |
Multivariate adjustments include age, sex, BMI, diabetes duration, current smoking habit, current alcohol intake, LTPA, sleep duration, HbA1c, UACR, systolic blood pressure, LDL cholesterol, history of CVD and cancer.
BMI, body mass index; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; LTPA, leisure-time physical activity; UACR, urinary albumin creatinine ratio.